Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146500 | 0.93 | ALDH1A1 (0.48) | ALDH1A1MAPK1EPHX2GAAMEN1 | |
| SCHEMBL2146495 | 0.93 | ALDH1A1 (0.48) | ALDH1A1MAPK1EPHX2GAAMEN1 | |
| SCHEMBL2146241 | 0.93 | ALDH1A1 (0.51) | ALDH1A1MAPK1EPHX2GAAMEN1 | |
| SCHEMBL2148505 | 0.93 | ALDH1A1 (0.51) | ALDH1A1MAPK1EPHX2GAAMEN1 | |
| SCHEMBL16992001 | 0.89 | MAPK1 (0.49) | ALDH1A1MAPK1EPHX2GAATDP1 | |
| SCHEMBL26140448 | 0.86 | L3MBTL1 (0.47) | ALDH1A1MAPK1EPHX2GAATDP1 | |
| SCHEMBL16072922 | 0.83 | KDM5A (0.47) | MEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL10205067 | 0.82 | POLB (0.48) | ALDH1A1MAPK1EPHX2GAAMEN1 | |
| SCHEMBL18626574 | 0.82 | BCHE (0.41) | ALDH1A1MAPK1KMT2ALMNA | |
| SCHEMBL18745372 | 0.82 | BCHE (0.41) | ALDH1A1MAPK1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-9938294-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885MAPK1 2058/4885EPHX2 3568/4885 |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885MAPK1 2058/4885EPHX2 3568/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | ALDH1A1 4703/4885MAPK1 2796/4885EPHX2 3485/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885MAPK1 2058/4885EPHX2 3568/4885 |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885MAPK1 2058/4885EPHX2 3568/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885MAPK1 2058/4885EPHX2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.